About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.Stay Connected
My Profile
I am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!About This Blog
Eye on FDA is published by Mark Senak of FleishmanHillard’s New York office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
Twitter List
Legislative Tracking Tools
Monthly Archives: October 2006
Send in the Clones
Today the Washington Post reports that the FDA is set to approve food and milk that comes from cloned animals. Is it possible then, that we may hear an abundance of deja vu related remarks around mealtime in the coming … Continue reading
Transparency and FDA Advisory Committees
The agency is not doing everything that it should in order to support transparency in the advisory committee process, and it needs to do more. The relationship between members of FDA Advisory Committees and the industry that produces the products … Continue reading
Posted in FDA Image
Comments Off on Transparency and FDA Advisory Committees
Weekly Roundup – 10/13/06
The days are truly shorter now. For the superstitious amongst us, it is an auspicious day ending this relatively quiet week. This morning it was so cold, one could see one’s breath upon exhaling, but the frost was not yet … Continue reading
Posted in Weekly Roundup
Comments Off on Weekly Roundup – 10/13/06
Should the FDA Drop Food from its Mandate?
All of the food woes of the past few weeks raise some serious questions which have been before considered, but merit re-visitation. First we had the spinach e-coli outbreak, the carrot juice botulism, the lettuce recall and a ground beef … Continue reading
Posted in Food
Comments Off on Should the FDA Drop Food from its Mandate?
Tracking Approvable Letters
There are three general outcomes from submitting a new drug to the FDA for approval. First – approval, for which everyone hopes. Second non-approval, which is the obvious bad scenario. Third are approvable letters, issued by the FDA when they … Continue reading
Posted in Regulatory Communications
Comments Off on Tracking Approvable Letters